How cbdMD earned WSJ coverage on FDA’s CBD regulation deferral

The FDA's decision (or indecision) to punt CBD regulation to Congress continues to send shockwaves through the cannabis industry. Reputable companies, like cbdMD, say this decision will continue to encourage bad-faith actors in the CBD space, harming every company striving for industry transparency. cbdMD's Chief Science Officer & Vice-President of Regulatory Affairs, Dr. Sibyl Swift, and General Counsel, Lance Blundell join the Move the Stairs™ podcast to discuss how the development is forcing change in its overall strategy to educate consumers and journalists while maintaining brand resiliency.